AUTHORS
Panagiotis Diamantopoulos, MD, PhD, Christos Stafylidis, MD, MSc2, Marina Mantzourani3, Anthi Bouchla4, Vasiliki Pappa, MD5, Paraskevi Giannikou6, Maria Pagoni, MD7, Aikaterini Kolotsiou8, Theodoros P. Vassilakopoulos9, Aikaterini Kosmidou, MD10, Antonia Syrigou, MD11, Ioanna-Georgia Zisimopoulou12, Vasiliki Lampropoulou13, Despoina Dimitriou14, Ioannis Kotsianidis, MD PhD15, Theodora Maria Venou16, Efthymia Vlachaki, MD, PhD, MBBS17, Elisavet Apostolidou18, Eleftheria Hatzimichael, MD19, Anna Karytianou20, Vasiliki Zina21, Christina Frouzaki22, Evdoxia Hatjiharissi, MD, PhD23, Maria Krithinaki, MD24, Christina Papis25, Athanasios Galanopoulos26, Charalampos G Pontikoglou27
AFFILIATIONS
1 National and Kapodistrian University of Athens, Athens, Greece
2 National and Kapodistrian University of Athens, Athens, Greece
3 National and Kapodistrian University of Athens, Athens, Greece
4 Attikon General Hospital, National and Kapodistrian University of Athens, Athens, Greece
5 Attikon General Hospital, National and Kapodistrian University of Athens, Athens, Greece
6 Evangelismos Hospital, Athens, Greece
7 Evangelismos Hospital, Athens, Greece
8 School of Medicine, National and Kapodistrian University of Athens, Laikon General Hospital, Athens, Greece., Athens, Greece
9 School of Medicine, National and Kapodistrian University of Athens, Laikon General Hospital, Athens, Greece., Athens, Greece
10 George Papanikolaou Hospital, Thessaloniki, Greece
11 George Papanikolaou Hospital, Thessaloniki, Greece
12 University Hospital of Patras, University of Patras, Rion, Greece
13 University Hospital of Patras, University of Patras, Rion, Greece
14 University Hospital of Alexandroupolis, Democritus University of Thrace, Alexandroupolis, Greece
15 University Hospital of Alexandroupolis, Democritus University of Thrace, Alexandroupolis, Greece
16 Hippokration General Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece
17 Hippokration General Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece
18 Faculty of Medicine, School of Health Sciences, University of Ioannina, Ioannina, Greece
19 Faculty of Medicine, School of Health Sciences, University of Ioannina, Ioannina, Greece
20 Gennimatas General Hospital, Athens, Greece
21 Gennimatas General Hospital, Athens, Greece
22 AHEPA University Hospital, Thessaloniki, Greece
23 AHEPA University Hospital, Thessaloniki, Greece
24 University Hospital of Heraklion, Heraklion, Greece
25 Euroclinic Athens, Athens, Greece
26 Euroclinic Athens, Athens, Greece
27 University Hospital of Heraklion, Heraklion, Greece
ABSTRACT
Introduction
Thrombopoietin-receptor agonists (TPO-RAs) are highly effective in the management of persistent and chronic primary immune thrombocytopenia (ITP). However, few real-world studies have evaluated the long-term outcomes of TPO-RAs, and no validated predictors of response have been identified.
Aim and methods
We performed a retrospective, multicenter analysis of a national registry of adult patients with primary ITP treated with TPO-RAs to evaluate response rates, time to response, factors associated with response, and outcomes after treatment discontinuation. The analysis included patients who had received at least one dose of a TPO-RA. Response was defined according to the International Working Group (IWG) criteria. Informed consent was obtained from all participants. The study was approved by the Ethics Committees of all participating Centers and was conducted in accordance with the Declaration of Helsinki.
Results
A total of 317 patients from 14 centers in Greece were included in the study; 38.7% were male, and the median age at TPO-RA initiation was 60.0 years. Before TPO-RAs, patients had received a median of 2 (0-5) treatment lines (95.9% corticosteroids +/- intravenous immunoglobulin [IVIG]). The initial TPO-RA was eltrombopag in the majority of patients (68.1%), followed by romiplostim (21.1%) and avatrombopag (10.4%). The median time from diagnosis to TPO-RA initiation was 8.0 (0.0-532.0) months. The main indication for TPO-RA initiation was steroid dependence (64.5%), followed by recurrent bleeding (25.9%), steroid intolerance (4.8%), and first-line treatment (4.8%).
Response to TPO-RAs was achieved by 82.0% of patients (complete response [CR], 67.4% and response [R], 14.6%), whereas 18.0% were non-responders (NR). Response was not associated with the baseline ITP bleeding assessment tool (BAT) score, the number of previous treatment lines, or prior treatments (corticosteroids, intravenous immunoglobulin, rituximab, splenectomy, immunosuppression). Moreover, response rates did not differ among the three different TPO-RAs administered. In contrast, a higher platelet (PLT) count before TPO-RA initiation was associated with response; the median baseline PLT count of responders was 25.5x109/L compared with 15.0x109/L in non-responders (p<0.001).
Median time to CR was 1.0 month and to R was 1.8 months. Time to response (CR/R) was not associated with sex, age, baseline ITP BAT score, PLT count before TPO-RA initiation, or the TPO-RA administered. In contrast, a longer interval from diagnosis to TPO-RA initiation was associated with a longer time to response (Spearman’s ρ=0.207; p=0.004). The same association was found with the number of previous treatment lines (0 or 1, vs >1, p=0.026). Moreover, time to CR was longer in patients with prior IVIG treatment (p=0.016) and in those with a previous splenectomy (1.0 month in non-splenectomized vs 4.0 months in splenectomized patients, p=0.029), but not with previous rituximab or other immunosuppressive therapy.
Overall, 21.8% of the patients discontinued TPO-RA after achieving sustained CR. Among those patients, relapse occurred in 33.3%. Median treatment-free remission (TfR) was not reached. Most relapses occurred within the first two years after TPO-RA discontinuation, whereas patients remaining treatment-free beyond this period had durable remissions. TfR was not associated with age, sex, previous treatment lines, or the indication for TPO-RA initiation. Baseline ITP-BAT score >1 was associated with longer (TfR) after TPO-RA discontinuation (log-rank p=0.018).
Discussion
To our knowledge, this is one of the largest real-world registries of patients with ITP treated with TPO-RAs. TPO-RAs induced responses in more than 80% of patients, with two-thirds achieving CR, irrespective of the TPO-RA used. Responses were rapid, with a median time to CR of only one month, and were affected by previous treatments, while time to CR was longer in patients with a longer disease course. Treatment discontinuation following sustained CR was feasible in a substantial proportion of patients. No baseline laboratory or treatment-related characteristics were associated with TfR, except for baseline ITP-BAT score. Our findings complement prospective discontinuation studies and recent real-world cohorts showing that sustained treatment-free responses are achievable in a considerable subset of patients, while late relapses appear to be uncommon.
DISCLOSURES
Charalampos G Pontikoglou: No relevant conflicts of interest to declare.